MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

AbbVie Inc

Cerrado

SectorSalud

190.72 0.54

Resumen

Variación precio

24h

Actual

Mínimo

188.4

Máximo

190.82

Métricas clave

By Trading Economics

Ingresos

1.3B

1.3B

Ventas

-1.8B

13B

P/B

Media del Sector

79.843

39.564

BPA

2.46

Rentabilidad por dividendo

3.53

Margen de beneficio

9.66

Empleados

55,000

EBITDA

3.2B

3.7B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+12.14% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.53%

2.40%

Próximas Ganancias

31 jul 2025

Fecha Próximo Dividendo

15 ago 2025

Próxima Fecha de Ex Dividendo

15 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-9B

334B

Apertura anterior

190.18

Cierre anterior

190.72

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

35 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

AbbVie Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 jun 2025, 13:02 UTC

Adquisiciones, fusiones, absorciones

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 abr 2025, 13:57 UTC

Ganancias

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 abr 2025, 12:52 UTC

Ganancias

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9 abr 2025, 18:18 UTC

Principales Movimientos del Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 abr 2025, 09:39 UTC

Principales Movimientos del Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30 jun 2025, 12:47 UTC

Adquisiciones, fusiones, absorciones

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 jun 2025, 12:33 UTC

Adquisiciones, fusiones, absorciones

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 jun 2025, 12:33 UTC

Adquisiciones, fusiones, absorciones

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 jun 2025, 12:32 UTC

Adquisiciones, fusiones, absorciones

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 jun 2025, 12:31 UTC

Adquisiciones, fusiones, absorciones

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 may 2025, 09:30 UTC

Principales Noticias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 abr 2025, 12:44 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 abr 2025, 09:33 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 abr 2025, 16:03 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 abr 2025, 14:00 UTC

Principales Noticias
Ganancias

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 12:24 UTC

Principales Noticias
Ganancias

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 12:03 UTC

Principales Noticias
Ganancias

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Net $1.29B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q EPS 72c >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Adj EPS $2.46 >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Rev $13.34B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 mar 2025, 15:04 UTC

Adquisiciones, fusiones, absorciones

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

AbbVie Inc Esperado

Precio Objetivo

By TipRanks

12.14% repunte

Estimación a 12 meses

Media 212.8 USD  12.14%

Máximo 250 USD

Mínimo 170 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

11

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

180.37 / 195.54Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

35 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.